Hp129 Xenon Imaging and BOS in Lung Transplantation

• Status: Recruiting
• Trial end date: 2027-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The research is being conducted to develop new imaging methods that are sufficiently sensitive to allow for early diagnosis of BOS, a chronic allograft rejection affecting 50-60% of lung transplanted recipients who survive 5 years after transplant. Although lung transplantation has evolved into an effective therapeutic option for a large number of pediatric patients with end-stage pulmonary disease, long-term survival after lung transplantation is far worse than after the transplantation of other solid organs. This research may improve patient outcomes through earlier diagnosis of changes leading to BOS by obtaining image guided research biopsies of transplanted lung. Biopsies may be used for future research of ex vivo biomarkers of BOS and in the development of treatments through future clinical trials.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital Medical Center, Cincinnati
• Treatments: Xenon

Criteria

Inclusion Criteria:

• Lung Transplantation within the last 10 years or being assessed for possible lung transplantation.

• Participant must be able to hold their breath for up to 16 seconds.

Exclusion Criteria:

• Standard MRI exclusion criteria

• Bleeding disorders

• Participant is claustrophobic or otherwise unable to tolerate the imaging

• Pregnancy or positive pregnancy test

• Symptoms of respiratory infection within the past two weeks.

• Baseline oximetry at MRI visit of less than 95% on room air or less than 95% on a previously prescribed dosage of oxygen delivered by nasal cannula.